Hyaluronidase (human recombinant)

ASH 2024 highlights include GSK's Blenrep Phase 3 data supporting re-market, J&J's Darzalex Faspro delaying progression in smoldering multiple myeloma, Arcellx's anito-cel showing comparable safety to Carvykti, and J&J/Legend's Carvykti improving survival outcomes. Kura Oncology's ziftomenib showed high response rates in leukemia, Eli Lilly's Jaypirca reduced disease progression risk, and Merck's zilovertamab vedotin achieved high complete response rates in lymphoma. Beam Therapeutics' BEAM-101 showed durable effects in sickle cell disease, Novo Nordisk's etavopivat reduced crises, and Bristol Myers Squibb's arlo-cel demonstrated durable responses in multiple myeloma. Galapagos' GLPG5101 showed encouraging cell therapy results, Orca Bio's Orca-T improved survival in blood cancers, and Sanofi's rilzabrutinib improved platelet response in thrombocytopenia. Regeneron's drug combo showed better disease control than Ultomiris in PNH.

Johnson & Johnson's Darzalex Faspro showed significant improvement in progression-free survival in high-risk smouldering multiple myeloma patients, with 63.1% remaining progression-free at 60 months vs 40.8% in active monitoring. Five-year survival rates were 93% with Darzalex Faspro vs 86.9% with monitoring, and response rates were 63.4% vs 2%. J&J has submitted regulatory applications based on these phase 3 AQUILA trial results.

Johnson & Johnson presents TECVAYLI data from MajesTEC-5 and MajesTEC-4 studies, showing potential in newly diagnosed multiple myeloma patients. Results include MRD negativity and manageable safety profiles, with further combination therapy analysis planned in MajesTEC-7.

Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data showing 100% MRD negativity in newly diagnosed multiple myeloma patients treated with MajesTEC-5 induction and MajesTEC-4 maintenance therapies, presented at the 2024 ASH Annual Meeting.

DARZALEX FASPRO® significantly delayed progression from high-risk SMM to active MM and extended overall survival in the Phase 3 AQUILA study, compared to active monitoring.

Nuvig Therapeutics develops a first-in-class drug targeting type II Fc receptors to expand regulatory T cells, aiming to treat autoimmune diseases without chronic immunosuppression. The company secured $161 million for Phase 2 development of NVG-2089, tested for chronic inflammatory demyelinating polyneuropathy (CIDP). Unlike FcRn blockers, Nuvig's drug is immunomodulatory, potentially offering broader efficacy in CIDP.

Belantamab mafodotin's comeback, FDA approvals for subcutaneous daratumumab-hyaluronidase and expanded CAR T-cell products, and isatuximab-based quadruplet emerging as new standard for transplant-ineligible newly diagnosed multiple myeloma patients.

Halozyme proposes to acquire Evotec for €11.00 per share, creating a leading global pharma services company with capabilities in drug discovery, biologic manufacturing, and drug delivery technologies, diversifying and scaling Halozyme's revenue and EBITDA into the next decade. The all-cash transaction would be funded by cash on hand and new debt, with expected net leverage less than 2x two years post-close.

Roche Holding AG CEO Thomas Schinecker is optimistic about the company's latest Alzheimer’s drug, which has shown effectiveness in breaking up amyloid plaques. The drugmaker presented its data at the CTAD medical conference. Roche's third-quarter sales rose 9% to 15.1 billion Swiss francs, driven by key medicines. The company confirmed its forecast for high-single-digit adjusted earnings per share growth.

Zai Lab reports Q3 2024 net product revenue growth of 47% y-o-y to $101.8M, positive China bridging study results for KarXT in schizophrenia, and global Phase 1 data suggesting best-in-class potential for ZL-1310 in extensive-stage SCLC. The company expects three product launches in China by end of 2024 and up to four NMPA regulatory submissions in the next six months. Cash position was $716.1M as of September 30, 2024.